Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement for Innovative Cancer Treatments
PR Newswire - Thu Apr 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.
Actinium Announces Further Development of Actimab-A Manufacturing
Business Wire - Mon Apr 07, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
Actinium CEO Interviewed for "Small Stocks: Big Money" Airing on Fox Business and Bloomberg
Business Wire - Thu Apr 03, 12:15PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
Actinium's shares listed on NYSE MKT to facilitate increased visibility and liquidity
M2 - Thu Mar 27, 5:14AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) revealed on Wednesday that its shares have begun trading as of 26 March 2014 on the NYSE MKT under the symbol "ATNM".
Actinium Commences Trading on NYSE MKT Today under the Symbol ATNM
Business Wire - Wed Mar 26, 8:30AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
Actinium to Commence Trading on NYSE MKT on March 26, 2014
Business Wire - Tue Mar 25, 9:05AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company"
Actinium to Present at BioCentury 21st Annual Future Leaders in the Biotech Industry Conference on March 28
Business Wire - Tue Mar 25, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
Actinium to begin trading on NYSE MKT on 26 March 2014
M2 - Tue Mar 25, 4:16AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) disclosed on Monday that it will commence trading on the New York Stock Exchange on 26 March 22014.
Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients
M2 - Tue Mar 25, 4:06AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) said on Monday that it has treated the first patient with Actimab-A drug candidate for newly diagnosed AML patients under its ongoing Phase 1/2 trial.
Actinium to List Common Stock on NYSE MKT
Business Wire - Mon Mar 24, 4:20PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
Actinium Announces Introduction of the New Lot of Lintuzumab into the Clinic
Business Wire - Mon Mar 24, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
Actinium to Present at 2nd Annual Sachs Cancer Bio Partnering & Investor Forum
Business Wire - Thu Mar 13, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013
Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"
Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference
Marketwire - Wed Feb 26, 7:08AM CST
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) ("Actinium" or "the Company"
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Global Radiopharmaceuticals Market Insight Research Report
M2 - Tue Feb 11, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8p2r/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly. A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market. Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities. The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018. Report Highlights: - Global Radio Pharmaceuticals Market Overview by Region - Target Patient Base by Region - Radiopharmaceuticals Market Regulation for US, Europe & Canada - Radioisotopes Used in Radiopharmaceuticals - Radiopharmaceutical Clinical Pipeline Insight - Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase Companies Mentioned - AREVA Med - Actinium Pharmaceuticals - Avid Radiopharmaceuticals - Bayer HealthCare Pharmaceuticals - Cardinal Health - GE Healthcare - Immunomedics - Ion Beam Applications - Lantheus Medical Imaging - Lantheus Medical Imaging - Merck & Co - Navidea - Nordion - PETNET Solutions (Siemens Healthcare Global) For more information visit http://www.researchandmarkets.com/research/px8p2r/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Actinium Presenting at the 16th Annual BIO CEO & Investor Conference Today at 1:30 pm ET
Business Wire - Tue Feb 11, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
Actinium to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"